It took more than 8 months and a series of sweetened offers, but Sanofi was able to close their $11.6B deal to buy Bioverativ without triggering an auction.
It took more than 8 months and a series of sweetened offers, but Sanofi was able to close their $11.6 billion deal to buy Bioverativ without triggering an auction. And in the process they made a new set of biotech millionaires, with Bioverativ CEO John Cox leading the pack with a payout worth more than $85 million.
